samedan logo
 
 
spacer
home > ict > winter 2018 > promising participation
PUBLICATIONS
International Clinical Trials

Promising Participation

In the history of medical research, the concept of patient centricity is a relatively new one. Until a few years ago, the primary focus of most clinical trials was developing drugs for commercial application. Patients were important and necessary to this process, but only because they represented the human connection to data the development team needed to move a drug candidate or treatment option through the regulatory approval process.

Unsurprisingly, patients who did become involved in clinical trials often felt disrespected and unimportant. As the industry accepted that patients’ generally low levels of satisfaction translated into compliance issues and high dropout rates, as well as broadly negative perceptions of clinical research that contribute to the limited participation rates of today, interest began to rise in assessing and addressing patient concerns.

By the mid-2000s, terms such as ‘patient centricity’ and ‘patientcentric trials’ had begun to find their way into publications and presentations. Although precise definitions vary, the underlying concept from the beginning is that providing patients with more information and greater integration into the trial process will lead to greater patient satisfaction and improved outcomes for sponsors, research centres, and patients.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Lea Studer is the Senior Vice President of Marketing Communications at SCORR marketing – a full-service marketing firm in the health sciences industry, and the lead organiser for the Bridging Clinical Research and Clinical Healthcare Collaborative. The collaborative was founded to bring together leaders from pharma, biotechnology, CROs, healthcare organisations, advocacy groups, and the FDA to focus on ways to advance healthcare through bridging regulatory, technology, and people and processes.
spacer
Lea Studer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>

White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

 
Industry Events

SMI Immuno-Oncology Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies, and SMi's Immuno-Oncology Conference will focus on a few key areas of the field with a representation of the whole industry under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement